Nektar Therapeutics (NKTR) - Total Liabilities
Based on the latest financial reports, Nektar Therapeutics (NKTR) has total liabilities worth $192.01 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Nektar Therapeutics (NKTR) investment intensity to see how much of total assets are deployed in long-term investments.
Nektar Therapeutics - Total Liabilities Trend (1994–2025)
This chart illustrates how Nektar Therapeutics's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Nektar Therapeutics (NKTR) total assets.
Nektar Therapeutics Competitors by Total Liabilities
The table below lists competitors of Nektar Therapeutics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Civitas Resources Inc
NYSE:CIVI
|
USA | $8.43 Billion |
|
Hanmi Science
KO:008930
|
Korea | ₩494.84 Billion |
|
Mister Car Wash, Inc. Common Stock
NASDAQ:MCW
|
USA | $2.03 Billion |
|
Tianma Microelectronics Co Ltd
SHE:000050
|
China | CN¥45.02 Billion |
|
Aether Industries Limited
NSE:AETHER
|
India | Rs7.46 Billion |
|
Zhejiang Yongtai Technology Co Ltd
SHE:002326
|
China | CN¥8.21 Billion |
|
Sellas Life Sciences Group Inc
NASDAQ:SLS
|
USA | $7.73 Million |
|
Thule Group AB
ST:THULE
|
Sweden | Skr6.51 Billion |
Liability Composition Analysis (1994–2025)
This chart breaks down Nektar Therapeutics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Nektar Therapeutics's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nektar Therapeutics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nektar Therapeutics (1994–2025)
The table below shows the annual total liabilities of Nektar Therapeutics from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $190.57 Million | -21.61% |
| 2024-12-31 | $243.11 Million | -8.96% |
| 2023-12-31 | $267.05 Million | -22.36% |
| 2022-12-31 | $343.96 Million | -21.41% |
| 2021-12-31 | $437.68 Million | -5.16% |
| 2020-12-31 | $461.47 Million | -19.32% |
| 2019-12-31 | $571.97 Million | +32.22% |
| 2018-12-31 | $432.60 Million | +2.75% |
| 2017-12-31 | $421.04 Million | -12.42% |
| 2016-12-31 | $480.75 Million | -3.00% |
| 2015-12-31 | $495.63 Million | +22.29% |
| 2014-12-31 | $405.29 Million | -22.72% |
| 2013-12-31 | $524.43 Million | +16.34% |
| 2012-12-31 | $450.77 Million | +10.28% |
| 2011-12-31 | $408.74 Million | -5.07% |
| 2010-12-31 | $430.56 Million | -9.00% |
| 2009-12-31 | $473.15 Million | +27.75% |
| 2008-12-31 | $370.38 Million | -27.47% |
| 2007-12-31 | $510.66 Million | -5.63% |
| 2006-12-31 | $541.12 Million | +1.76% |
| 2005-12-31 | $531.74 Million | +91.56% |
| 2004-12-31 | $277.58 Million | -38.67% |
| 2003-12-31 | $452.60 Million | +13.19% |
| 2002-12-31 | $399.87 Million | +0.74% |
| 2001-12-31 | $396.93 Million | +12.87% |
| 2000-12-31 | $351.66 Million | +150.87% |
| 1999-12-31 | $140.18 Million | +653.03% |
| 1998-12-31 | $18.61 Million | -17.88% |
| 1997-12-31 | $22.67 Million | +254.20% |
| 1996-12-31 | $6.40 Million | +113.33% |
| 1995-12-31 | $3.00 Million | +66.67% |
| 1994-12-31 | $1.80 Million | -- |
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosi… Read more